Tuba Ersal, F. Özkalemkaş, V. Ozkocaman, Ibrahim Ethem Pınar, Cumali Yalçın, B. Orhan, Ömer Candar, Sinem Çubukçu, Tuba Güllü Koca, R. Ali
Background Hairy cell leukemia (HCL) is an uncommon neoplasm representing approximately 2% leukemias and
毛细胞白血病(HCL)是一种罕见的肿瘤，约占白血病发病率的2%
{"title":"Results of Subcutaneous and Intravenous Cladribine Treatment in Hairy Cell Leukemia Patients: A single-center Experience","authors":"Tuba Ersal, F. Özkalemkaş, V. Ozkocaman, Ibrahim Ethem Pınar, Cumali Yalçın, B. Orhan, Ömer Candar, Sinem Çubukçu, Tuba Güllü Koca, R. Ali","doi":"10.46310/tjim.1239905","DOIUrl":"https://doi.org/10.46310/tjim.1239905","url":null,"abstract":"Background Hairy cell leukemia (HCL) is an uncommon neoplasm representing approximately 2% leukemias and","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"155 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73116814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Hunutlu, F. Özkalemkaş, Vildan Gürsoy, V. Ozkocaman
Background Autologous hematopoietic stem cell transplantation (AHSCT) is one of the standard treatment modalities for patients with multiple myeloma (MM) under 65 years of age. Renal failure, significant disease comorbidity, significantly affects treatment choices. There are conflicting data in the literature regarding the dose of melphalan to be used for AHSCT in patients with renal failure and comorbid conditions. This study aimed to compare the efficacy and side effect data of different melphalan doses in patients with renal failure. Material and Methods The study included 107 patients older than 18 years of age with a diagnosis of MM who underwent AHSCT in our center between January 2010 and January 2019. The data of the patients were analyzed retrospectively. Patients were grouped according to estimated glomerular filtration rate (eGFR:
{"title":"Mel-200 Or Mel-140 , Which One İs More Advantageous? Retrospectively Analysis Of The Multiple Myeloma Patients Treated With Autologous Hematopoetic Stem Cell Transplantation","authors":"F. Hunutlu, F. Özkalemkaş, Vildan Gürsoy, V. Ozkocaman","doi":"10.46310/tjim.1223288","DOIUrl":"https://doi.org/10.46310/tjim.1223288","url":null,"abstract":"Background Autologous hematopoietic stem cell transplantation (AHSCT) is one of the standard treatment modalities for patients with multiple myeloma (MM) under 65 years of age. Renal failure, significant disease comorbidity, significantly affects treatment choices. There are conflicting data in the literature regarding the dose of melphalan to be used for AHSCT in patients with renal failure and comorbid conditions. This study aimed to compare the efficacy and side effect data of different melphalan doses in patients with renal failure. \u0000Material and Methods The study included 107 patients older than 18 years of age with a diagnosis of MM who underwent AHSCT in our center between January 2010 and January 2019. The data of the patients were analyzed retrospectively. Patients were grouped according to estimated glomerular filtration rate (eGFR:","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87388235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Erectile dysfunction (ED) may be associated with chemotherapy and depression in lymphoma patients. The role of depression in developing ED in lymphoma patients may be more critical than chemotherapy. This study aimed to determine which plays a more important role in ED. Material and Methods This study included 20 patients aged under 60 years who were admitted to the Hematology Outpatient Clinic between March 2015 and March 2016 and diagnosed with lymphoma. While the Beck Depression Inventory (BDI) was used to assess depression severity before (T1), during (T2) and after (T3) chemotherapy, the International Index of Erectile Function (IIEF) was used to assess sexual function. The Mann-Whitney U and Wilcoxon signed-rank tests were used for statistical analysis. A p-value of
{"title":"What is the main reason of erectile dysfunction in lymphoma patients: Chemotherapy or Depression?","authors":"Cumali Yalçın, A. Erdoğan, G. Yılmaz","doi":"10.46310/tjim.1210699","DOIUrl":"https://doi.org/10.46310/tjim.1210699","url":null,"abstract":"Background Erectile dysfunction (ED) may be associated with chemotherapy and depression in lymphoma patients. The role of depression in developing ED in lymphoma patients may be more critical than chemotherapy. This study aimed to determine which plays a more important role in ED. \u0000Material and Methods This study included 20 patients aged under 60 years who were admitted to the Hematology Outpatient Clinic between March 2015 and March 2016 and diagnosed with lymphoma. While the Beck Depression Inventory (BDI) was used to assess depression severity before (T1), during (T2) and after (T3) chemotherapy, the International Index of Erectile Function (IIEF) was used to assess sexual function. The Mann-Whitney U and Wilcoxon signed-rank tests were used for statistical analysis. A p-value of","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83957419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Kidney involvement is seen frequently in COVID-19 patients and is essential to the prognosis. This study is undertaken to describe the clinical presentation of renal involvement in COVID-19 patients concerning acute kidney injury (AKI), chronic kidney disease (CKD), and urinary abnormalities and to correlate with the severity of COVID-19 illness and its outcome. Material and Methods A retrospective cross-sectional study reviewed the medical records of patients admitted with COVID-19 infection who had pre-existing renal conditions or renal manifestations in the form of deranged renal function tests or abnormal urinary findings. All the relevant clinical and laboratory parameters, including the treatment details and outcome, were noted, and statistical analysis was done. Results A total of 72 out of 1,544 patients satisfied the inclusion criteria. Hypertension (72%) and Diabetes (62%) were the commonest co-morbidities noted. CKD was seen in 51 (70%) patients, and 21 patients (29%) were on maintenance dialysis. 39 (76%) patients with CKD were diagnosed with severe COVID-19, 25 (49%) of the patients developed acute worsening of CKD, and 45% had mortality. AKI was seen in 19 patients (26%). Urinary abnormality was seen in 34 (47%) patients, out of which 27 (37%) had proteinuria of more than 1+. Haematuria was seen in 27 (37.5%) patients, of which 12(17%) had gross haematuria. Dialysis was required in 24 patients (33%) additionally. Mechanical ventilation was required in 32(44%) patients, and inotropes in 41(56%). 21 (29%) patients developed acute respiratory distress syndrome, 39 (54%) had sepsis, with six patients developing multiorgan dysfunction syndrome. 62.5% of patients had mortality. The presence of other comorbid conditions, thrombocytopenia, coagulopathy, abnormality in arterial blood gases, and usage of inotropes were found to be significantly associated with adverse outcomes. Conclusions Most cases had severe renal system involvement, with an AKI prevalence rate of 1.2% and a case-specific mortality rate of 62.5%.
{"title":"Renal Involvement and Outcomes in Patients Hospitalized with COVID-19 Infection in A Tertiary Hospital","authors":"Sahana K.S., Santhosh BH PAİ, Rony George","doi":"10.46310/tjim.1209442","DOIUrl":"https://doi.org/10.46310/tjim.1209442","url":null,"abstract":"Background Kidney involvement is seen frequently in COVID-19 patients and is essential to the prognosis. This study is undertaken to describe the clinical presentation of renal involvement in COVID-19 patients concerning acute kidney injury (AKI), chronic kidney disease (CKD), and urinary abnormalities and to correlate with the severity of COVID-19 illness and its outcome. \u0000Material and Methods A retrospective cross-sectional study reviewed the medical records of patients admitted with COVID-19 infection who had pre-existing renal conditions or renal manifestations in the form of deranged renal function tests or abnormal urinary findings. All the relevant clinical and laboratory parameters, including the treatment details and outcome, were noted, and statistical analysis was done. \u0000Results A total of 72 out of 1,544 patients satisfied the inclusion criteria. Hypertension (72%) and Diabetes (62%) were the commonest co-morbidities noted. CKD was seen in 51 (70%) patients, and 21 patients (29%) were on maintenance dialysis. 39 (76%) patients with CKD were diagnosed with severe COVID-19, 25 (49%) of the patients developed acute worsening of CKD, and 45% had mortality. AKI was seen in 19 patients (26%). Urinary abnormality was seen in 34 (47%) patients, out of which 27 (37%) had proteinuria of more than 1+. Haematuria was seen in 27 (37.5%) patients, of which 12(17%) had gross haematuria. Dialysis was required in 24 patients (33%) additionally. Mechanical ventilation was required in 32(44%) patients, and inotropes in 41(56%). 21 (29%) patients developed acute respiratory distress syndrome, 39 (54%) had sepsis, with six patients developing multiorgan dysfunction syndrome. 62.5% of patients had mortality. The presence of other comorbid conditions, thrombocytopenia, coagulopathy, abnormality in arterial blood gases, and usage of inotropes were found to be significantly associated with adverse outcomes. \u0000Conclusions Most cases had severe renal system involvement, with an AKI prevalence rate of 1.2% and a case-specific mortality rate of 62.5%.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"138 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73145427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bacterial co-infections in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia are not very common as the prevalence of co-infections with other respiratory viruses. The rate of bacterial co-infection in hospitalized patients infected with influenza is higher than 30%, whereas it is lower than 4% in hospitalized patients with SARS-CoV-2. Respiratory viral infections associated with bacterial co-infection have higher mortality and morbidity rates. The literature shows that most SARS-CoV-2 patients admitted to the hospital do not necessarily screen for bacterial infections and antimicrobial susceptibility. Therefore, clinicians' misdiagnosis of these co-infections can pose a significant risk to the lives of vulnerable patients with COVID-19. In that light, we presented a complicated case of methicillin-resistant Staphylococcus aureus.
{"title":"A Case Report of Methicillin-Resistant Staph. aureus Coinfection in COVID-19 in the Intensive Care Unit","authors":"Ijaz Ahmad, Ibrar Khan, Shahab Khan, H. Khan","doi":"10.46310/tjim.1192956","DOIUrl":"https://doi.org/10.46310/tjim.1192956","url":null,"abstract":"Bacterial co-infections in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia are not very common as the prevalence of co-infections with other respiratory viruses. The rate of bacterial co-infection in hospitalized patients infected with influenza is higher than 30%, whereas it is lower than 4% in hospitalized patients with SARS-CoV-2. Respiratory viral infections associated with bacterial co-infection have higher mortality and morbidity rates. The literature shows that most SARS-CoV-2 patients admitted to the hospital do not necessarily screen for bacterial infections and antimicrobial susceptibility. Therefore, clinicians' misdiagnosis of these co-infections can pose a significant risk to the lives of vulnerable patients with COVID-19. In that light, we presented a complicated case of methicillin-resistant Staphylococcus aureus.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78377762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Prolonged hospitalization, prolonged neutropenia, and immunosuppressive treatments increase bloodstream infections in hematological patients. Identifying risk factors for carbapenem-resistant Klebsiella pneumonia (CRKP) infection will shed light on controlling the spread of CRKP. Our retrospective study aimed to determine the clinical features, antimicrobial susceptibility, and mortality risk factors of patients who developed CRKP in patients followed up for hematological cancer in the Izmir University of Economics Haematology Department. Material and Methods 19,170 blood-urine-sputum cultures were delivered from the patients, 1,595 (8.31%) of which presented growth. CRKP comprised 302 (1.57%) of such growth cases. The study included 72 patients with hematological malignancy who presented CRKP growth in 302 cultures obtained during the neutropenic fever period. Results The mean age of patients was 51 (18-75 years). Acute myeloid leukemia was the most common disease (n: 26, 36.11%). As to the antibiotic sensitivity of CRKP, 44 patients (61.1%) were colistin sensitive, 28 patients (38.9%) were colistin-resistant, 47 patients (65.3%) were tigecycline sensitive/medium sensitivity, 25 patients (34.7%) were tigecycline resistant, there was no statistically significant difference between antibiotic sensitivities and survival. Conclusions Today, early detection of CRKP colonization in high-risk hematological patients, taking rectal culture, and if the patient presents rectal colonization of CRKP or had CRKP bacteremia during prior hospitalizations, early initiation of treatment with antibiotics acting against CRKP during NPF would significantly reduce mortality.
{"title":"Risk factors and outcomes for carbapenem-resistant klebsiella pneumoniae in hematological patients","authors":"S. Kahraman, Gülfem TEREK ECE, S. Cagirgan","doi":"10.46310/tjim.1167548","DOIUrl":"https://doi.org/10.46310/tjim.1167548","url":null,"abstract":"Background Prolonged hospitalization, prolonged neutropenia, and immunosuppressive treatments increase bloodstream infections in hematological patients. Identifying risk factors for carbapenem-resistant Klebsiella pneumonia (CRKP) infection will shed light on controlling the spread of CRKP. Our retrospective study aimed to determine the clinical features, antimicrobial susceptibility, and mortality risk factors of patients who developed CRKP in patients followed up for hematological cancer in the Izmir University of Economics Haematology Department. \u0000Material and Methods 19,170 blood-urine-sputum cultures were delivered from the patients, 1,595 (8.31%) of which presented growth. CRKP comprised 302 (1.57%) of such growth cases. The study included 72 patients with hematological malignancy who presented CRKP growth in 302 cultures obtained during the neutropenic fever period. \u0000Results The mean age of patients was 51 (18-75 years). Acute myeloid leukemia was the most common disease (n: 26, 36.11%). As to the antibiotic sensitivity of CRKP, 44 patients (61.1%) were colistin sensitive, 28 patients (38.9%) were colistin-resistant, 47 patients (65.3%) were tigecycline sensitive/medium sensitivity, 25 patients (34.7%) were tigecycline resistant, there was no statistically significant difference between antibiotic sensitivities and survival. \u0000Conclusions Today, early detection of CRKP colonization in high-risk hematological patients, taking rectal culture, and if the patient presents rectal colonization of CRKP or had CRKP bacteremia during prior hospitalizations, early initiation of treatment with antibiotics acting against CRKP during NPF would significantly reduce mortality.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85289958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tuba ERÜRKER ÖZTÜRK, Selim GÜREL, Ayşegül ORUÇ, Alparslan ERSOY
Background Interferon and ribavirin treatments previously used in treating chronic hepatitis C virus (HCV) infection cannot be used effectively in hemodialysis patients due to dose adjustment and drug-related side effects. Direct-acting antivirals (DAAs) therapies have been reported to be effective in hemodialysis patients. This study aimed to evaluate the effectiveness of DAAs in hemodialysis patients with chronic hepatitis C.
Material and Methods Twenty hemodialysis patients with chronic hepatitis C followed in the gastroenterology outpatient clinic between 2016 and 2018 were evaluated retrospectively.
Results Twelve of the 20 patients were male, and eight were female. The mean age of the patients was 50.7±8.6 years. Six patients had no treatment experience. Fourteen patients had been previously treated with interferon and/or ribavirin but did not achieve sustained virological response (SVR). Genotype 1b was detected in 14 patients, genotype 1a in 4 patients, and genotype 1 in 2 patients. Patients were treated with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) and dasabuvir (DSV) or ribavirin (RBV) for 12 or 24 weeks. Two patients were cirrhotic and had a Child-Pugh score of A. Treatment was discontinued in 2 patients due to thrombus formation in the arteriovenous fistula in the first month of DAAs treatment. SVR12 was evaluated in 14 of 18 patients and found to be 100%. One of the ten patients accepted as SVR24 had a relapse. This rate of SVR24 was similar to that in the general population.
Conclusions Our results supported that the OBV/PTV/r and DSV or RBV regimen was a safe and effective therapy for hemodialysis patients with chronic hepatitis C virus genotype 1.
{"title":"The efficacy of the direct-acting antiviral combination in hemodialysis patients with chronic hepatitis C virus Genotype 1 infection","authors":"Tuba ERÜRKER ÖZTÜRK, Selim GÜREL, Ayşegül ORUÇ, Alparslan ERSOY","doi":"10.46310/tjim.994659","DOIUrl":"https://doi.org/10.46310/tjim.994659","url":null,"abstract":"Background Interferon and ribavirin treatments previously used in treating chronic hepatitis C virus (HCV) infection cannot be used effectively in hemodialysis patients due to dose adjustment and drug-related side effects. Direct-acting antivirals (DAAs) therapies have been reported to be effective in hemodialysis patients. This study aimed to evaluate the effectiveness of DAAs in hemodialysis patients with chronic hepatitis C.
 Material and Methods Twenty hemodialysis patients with chronic hepatitis C followed in the gastroenterology outpatient clinic between 2016 and 2018 were evaluated retrospectively.
 Results Twelve of the 20 patients were male, and eight were female. The mean age of the patients was 50.7±8.6 years. Six patients had no treatment experience. Fourteen patients had been previously treated with interferon and/or ribavirin but did not achieve sustained virological response (SVR). Genotype 1b was detected in 14 patients, genotype 1a in 4 patients, and genotype 1 in 2 patients. Patients were treated with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) and dasabuvir (DSV) or ribavirin (RBV) for 12 or 24 weeks. Two patients were cirrhotic and had a Child-Pugh score of A. Treatment was discontinued in 2 patients due to thrombus formation in the arteriovenous fistula in the first month of DAAs treatment. SVR12 was evaluated in 14 of 18 patients and found to be 100%. One of the ten patients accepted as SVR24 had a relapse. This rate of SVR24 was similar to that in the general population.
 Conclusions Our results supported that the OBV/PTV/r and DSV or RBV regimen was a safe and effective therapy for hemodialysis patients with chronic hepatitis C virus genotype 1.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"167 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135650928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fethi Yönet, I. Baloglu, Çiğdem KUCUR YÖNET, M. Dündar, H. Ozer, Yasin Öztürk, Kultigin Türkmen
Background Hearing and the auditory pathway are affected in Fabry diseases (FD). There is limited data on hearing and auditory pathways in this population. Therefore, we aimed to investigate auditory functions and auditory pathways using auditory brainstem responses (ABR), otoacoustic distortion emission (DPOAE), pure tone audiometry (PTA), and tympanometry in patients with FD and to compare these results with those of healthy individuals. Material and Methods This study included 16 patients with FD (F/M: 8/8, age: 33.5±15.4 years) and 16 healthy controls (F/M: 5/11, age: 33.6±6.3 years). Hearing functions and auditory pathways were assessed with ABR, DPOAE, PTA, and tympanometry. Results According to the results of PTA, conductive hearing loss was detected in 4 (25%) of the patients with FD. When the 500-4,000 Hz frequencies were assessed, the bone pathway hearing threshold in both ears was significantly higher in the patients with FD than in the control group (p=0.014 and p=0.014, respectively). When we compared the DPOAE measurements of the patients with FD and the control groups, the dB value measured at 2.8 kHz was significantly lower in the patient group than in the control group (p=0.018). When we compared the ABR measurements, the right ear's 3-5 interpeak latency at 60 dB was significantly lower in the patient with FD than in the control group (1.8±0.3 ms vs 2±0.2 ms, p=0.033). Conclusions We found that the hearing loss rate and hearing threshold were statistically significantly higher in FD patients than in the control group. Hearing screening should be systematically performed in these patients.
背景法布里病(FD)患者的听力和听觉通路受到影响。关于这一人群的听力和听觉通路的数据有限。因此，我们旨在通过听觉脑干反应(ABR)、耳声失真发射(DPOAE)、纯音测听(PTA)和鼓室测量来研究FD患者的听觉功能和听觉通路，并将这些结果与健康人的结果进行比较。材料与方法本研究纳入16例FD患者(F/M: 8/8，年龄:33.5±15.4岁)和16例健康对照(F/M: 5/11，年龄:33.6±6.3岁)。用ABR、DPOAE、PTA和鼓室测量法评估听力功能和听觉通路。结果根据PTA结果，4例(25%)FD患者出现传导性听力损失。当评估500-4,000 Hz频率时，FD患者双耳骨通路听力阈值显著高于对照组(p=0.014和p=0.014)。当我们比较FD患者和对照组的DPOAE测量值时，患者组在2.8 kHz测量的dB值明显低于对照组(p=0.018)。当我们比较ABR测量值时，FD患者的右耳3-5峰间潜伏期明显低于对照组(1.8±0.3 ms vs 2±0.2 ms, p=0.033)。结论FD患者的听力损失率和听力阈值明显高于对照组。这些患者应系统地进行听力筛查。
{"title":"Evaluation of Hearing and Auditory Pathways in Fabry Disease Patients","authors":"Fethi Yönet, I. Baloglu, Çiğdem KUCUR YÖNET, M. Dündar, H. Ozer, Yasin Öztürk, Kultigin Türkmen","doi":"10.46310/tjim.1209122","DOIUrl":"https://doi.org/10.46310/tjim.1209122","url":null,"abstract":"Background Hearing and the auditory pathway are affected in Fabry diseases (FD). There is limited data on hearing and auditory pathways in this population. Therefore, we aimed to investigate auditory functions and auditory pathways using auditory brainstem responses (ABR), otoacoustic distortion emission (DPOAE), pure tone audiometry (PTA), and tympanometry in patients with FD and to compare these results with those of healthy individuals. \u0000Material and Methods This study included 16 patients with FD (F/M: 8/8, age: 33.5±15.4 years) and 16 healthy controls (F/M: 5/11, age: 33.6±6.3 years). Hearing functions and auditory pathways were assessed with ABR, DPOAE, PTA, and tympanometry. \u0000Results According to the results of PTA, conductive hearing loss was detected in 4 (25%) of the patients with FD. When the 500-4,000 Hz frequencies were assessed, the bone pathway hearing threshold in both ears was significantly higher in the patients with FD than in the control group (p=0.014 and p=0.014, respectively). When we compared the DPOAE measurements of the patients with FD and the control groups, the dB value measured at 2.8 kHz was significantly lower in the patient group than in the control group (p=0.018). When we compared the ABR measurements, the right ear's 3-5 interpeak latency at 60 dB was significantly lower in the patient with FD than in the control group (1.8±0.3 ms vs 2±0.2 ms, p=0.033). \u0000Conclusions We found that the hearing loss rate and hearing threshold were statistically significantly higher in FD patients than in the control group. Hearing screening should be systematically performed in these patients.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73893652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Chelikikj, L. Poposka, Elena Grueva, E. Kandi̇c, Oliver Bushljeti̇kj, Zhan Zi̇mbakov
Acute limb ischemia is rare in patients with venous thromboembolism who already receive anticoagulation treatment. Inflammation is a risk factor for thrombus formation. Patients with active ulcerative colitis, especially at the time of exacerbation, are more prone to thromboembolism, both venous and arterial. The risk for thrombosis is 18% higher, with a higher risk of bleeding. To date, there is no contraindication to any anticoagulant drug in patients with ulcerative colitis. We represent a case of a 73 year - old woman with ulcerative colitis exacerbation, hospitalized initially for pulmonary thromboembolism, that developed acute arterial thrombosis when switched on a novel oral anticoagulant.
{"title":"Acute arterial thrombosis in anticoagulated patient for acute pulmonary thromboembolism","authors":"Ana Chelikikj, L. Poposka, Elena Grueva, E. Kandi̇c, Oliver Bushljeti̇kj, Zhan Zi̇mbakov","doi":"10.46310/tjim.1176071","DOIUrl":"https://doi.org/10.46310/tjim.1176071","url":null,"abstract":"Acute limb ischemia is rare in patients with venous thromboembolism who already receive anticoagulation treatment. Inflammation is a risk factor for thrombus formation. Patients with active ulcerative colitis, especially at the time of exacerbation, are more prone to thromboembolism, both venous and arterial. The risk for thrombosis is 18% higher, with a higher risk of bleeding. To date, there is no contraindication to any anticoagulant drug in patients with ulcerative colitis. We represent a case of a 73 year - old woman with ulcerative colitis exacerbation, hospitalized initially for pulmonary thromboembolism, that developed acute arterial thrombosis when switched on a novel oral anticoagulant.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86867951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ömer Candar, R. Ali, F. Özkalemkaş, Tuba Güllü Koca, Sinem Çubukçu, B. Orhan, Cumali Yalçın, Ibrahim Ethem Pınar, Tuba Ersal, V. Ozkocaman, Tuğçe ZOR TURNA
Background: Dapsone is a second-line therapy for immune thrombocytopenia (ITP). It is cost-effective, with a response rate comparable to other drugs used as second-line therapy, such as azathioprine, danazol, cyclophosphamide, cyclosporine, vincristine, rituximab, and eltrombopag. Material and Methods: This retrospective study analyzed ten adult patients who presented to our hematology division outpatient clinic between March 2013 and July 2021, was diagnosed with chronic/refractory ITP, did not respond to first-line therapy, and used dapsone. Results: Eight (80%) patients were female, and 2 (20%) were male. The median age was 50 (range, 24-64) years. The mean pre-treatment platelet value was 12.8x109/L (range: 4-22.1x109/L). The median duration of symptoms before dapsone treatment was 60 (6-360) months. The median number of treatments received before dapsone was 4 (range: 3-6). All patients were routinely treated with oral dapsone 50 mg for two weeks, followed by 100 mg. The median time to treatment response was 39 (range: 14-90) days. The response rate was 60% (complete response 40%, partial response 20%). Asymptomatic anemia was observed as a side effect in only one patient. Conclusions: Based on these results, it can be speculated that dapsone is an effective, inexpensive, and well tolerated treatment option. Considering the economic status of developing countries, it seems very attractive to use dapsone as the second-line therapy for chronic/refractory ITP. To the best of our knowledge, this is the first study in Turkey on the use of dapsone for chronic/refractory ITP.
{"title":"Use of dapsone in chronic/refractory immune thrombocytopenic patients: A single center experience","authors":"Ömer Candar, R. Ali, F. Özkalemkaş, Tuba Güllü Koca, Sinem Çubukçu, B. Orhan, Cumali Yalçın, Ibrahim Ethem Pınar, Tuba Ersal, V. Ozkocaman, Tuğçe ZOR TURNA","doi":"10.46310/tjim.1211506","DOIUrl":"https://doi.org/10.46310/tjim.1211506","url":null,"abstract":"Background: Dapsone is a second-line therapy for immune thrombocytopenia (ITP). It is cost-effective, with a response rate comparable to other drugs used as second-line therapy, such as azathioprine, danazol, cyclophosphamide, cyclosporine, vincristine, rituximab, and eltrombopag. \u0000Material and Methods: This retrospective study analyzed ten adult patients who presented to our hematology division outpatient clinic between March 2013 and July 2021, was diagnosed with chronic/refractory ITP, did not respond to first-line therapy, and used dapsone. \u0000Results: Eight (80%) patients were female, and 2 (20%) were male. The median age was 50 (range, 24-64) years. The mean pre-treatment platelet value was 12.8x109/L (range: 4-22.1x109/L). The median duration of symptoms before dapsone treatment was 60 (6-360) months. The median number of treatments received before dapsone was 4 (range: 3-6). All patients were routinely treated with oral dapsone 50 mg for two weeks, followed by 100 mg. The median time to treatment response was 39 (range: 14-90) days. The response rate was 60% (complete response 40%, partial response 20%). Asymptomatic anemia was observed as a side effect in only one patient. \u0000Conclusions: Based on these results, it can be speculated that dapsone is an effective, inexpensive, and well tolerated \u0000treatment option. Considering the economic status of developing countries, it seems very attractive \u0000to use dapsone as the second-line therapy for chronic/refractory ITP. To the best of our knowledge, this is the \u0000first study in Turkey on the use of dapsone for chronic/refractory ITP.","PeriodicalId":23372,"journal":{"name":"Turkish Journal of Internal Medicine","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78286740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：